Live Breaking News & Updates on Helmsley Trust Professor

Stay updated with breaking news from Helmsley trust professor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FARAPULSE's Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation


FARAPULSE s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation
News provided by
Share this article
Share this article
Pioneering technology has demonstrated potential to improve safety for patients with paroxysmal atrial fibrillation and simplify procedures for physicians
MENLO PARK, Calif., March 3, 2021 /PRNewswire/ - FARAPULSE Inc. today announced the first patients were treated in the
ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes them five times more likely to have a stroke than individuals with a regular heartbeat. The first patients were treated at New York s Mount Sinai Hospital by Dr. ....

United States , Allan Zingeler , Vivek Reddy , Icahn School Of Medicine At Mount Sinai , Journal Of The American College Cardiology , Drug Administration , Mount Sinai Health System , Helmsley Trust Professor Of Medicine , Investigational Device Exemption , Pulsed Field Ablation , Atrial Fibrillation , New York , Mount Sinai Hospital , Helmsley Trust Professor , Icahn School , Mount Sinai , Sinai Heart , American College , Cardiac Electrophysiology , Farapulse Inc , ஒன்றுபட்டது மாநிலங்களில் , விவேக் சிவப்பு , இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை , இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல் , ஏற்ற சினை ஆரோக்கியம் அமைப்பு , துடிப்பு புலம் நீக்கம் ,

First AF Patients Treated With Farapulse Pulsed Field Ablation System


First AF Patients Treated With Farapulse Pulsed Field Ablation System
Pioneering technology may simplify procedures and improve outcomes for patients with paroxysmal atrial fibrillation
March 3, 2021 Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal atrial fibrillation (AF). 
The first patients were treated at New York s Mount Sinai Hospital by Vivek Reddy, M.D., the Helmsley Trust Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the trial s principal investigator. ....

United States , Allan Zingeler , Vivek Reddy , Icahn School Of Medicine At Mount Sinai , Journal Of The American College Cardiology , Farapulse Inc , Drug Administration , Mount Sinai Health System , Helmsley Trust Professor Of Medicine , Pulsed Field Ablation , New York , Mount Sinai Hospital , Helmsley Trust Professor , Icahn School , Mount Sinai , Sinai Heart , American College , Cardiac Electrophysiology , ஒன்றுபட்டது மாநிலங்களில் , விவேக் சிவப்பு , இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை , இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல் , ஏற்ற சினை ஆரோக்கியம் அமைப்பு , துடிப்பு புலம் நீக்கம் , புதியது யார்க் , ஏற்ற சினை மருத்துவமனை ,